Cargando…
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury
The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are few reports on necroptosis in ALF. Therefore, we evaluated th...
Autores principales: | Kondo, Takayuki, Fujimoto, Kentaro, Fujiwara, Kisako, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Nakagawa, Miyuki, Iwanaga, Terunao, Koroki, Keisuke, Kanzaki, Hiroaki, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Ogasawara, Sadahisa, Nakamoto, Shingo, Chiba, Tetsuhiro, Kato, Jun, Fujiwara, Keiichi, Kato, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462689/ https://www.ncbi.nlm.nih.gov/pubmed/37640752 http://dx.doi.org/10.1038/s41598-023-41425-6 |
Ejemplares similares
-
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients
por: Kondo, Takayuki, et al.
Publicado: (2023) -
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B Virus
por: Ma, Yaojia, et al.
Publicado: (2022) -
The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma
por: Kondo, Takayuki, et al.
Publicado: (2022) -
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial
por: Ogasawara, Sadahisa, et al.
Publicado: (2022) -
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
por: Kanogawa, Naoya, et al.
Publicado: (2023)